Soliton, Inc. Stock

SOLY

US8342511008

Advanced Medical Equipment & Technology

Analysts' recommendations : Soliton, Inc.

02/06/21	Soliton : Roth Capital Downgrades Soliton to Neutral From Buy	MT
13/05/21	Soliton : Cantor Fitzgerald Downgrades Soliton to Neutral from Overweight, Adjusts Price Target to $22.60 from $25	MT
11/05/21	Soliton : Maxim Group Downgrades Soliton to Hold From Buy	MT
02/02/21	Soliton : Cantor Fitzgerald Adjusts Soliton's Price Target to $20 from $12, Keeps Overweight Rating	MT

More recommendations

Press Releases : Soliton, Inc.

16/12/21	SOLITON, INC. : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	AQ
16/12/21	Allergan Aesthetics Completes Acquisition of Soliton	PR
15/12/21	SOLITON, INC. : Other Events (form 8-K)	AQ
13/11/21	SOLITON, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	AQ
09/11/21	SOLITON, INC. : Other Events (form 8-K)	AQ

More press releases

Managers and Directors : Soliton, Inc.

Manager	Title	Age	Since
Joseph D. Tanner COO	Chief Operating Officer	79	01/09/2014
Mary Stoll PRN	Corporate Officer/Principal	-	01/03/2021

More insiders

Soliton Inc is a medical technology company. The Company is focused on developing and commercializing products utilizing its designed acoustic shockwave technology platform referred to as Rapid Acoustic Pulse (RAP). It develops products for the removal of tattoos and the reduction of cellulite. The RAP device in coordination with the pulsed laser removes ink pigment from the macrophages. Its RAP device uses pulses of designed acoustic shockwaves to disrupt cellular structures in the dermal and subdermal tissue. It's designed shockwave allows it to target the stiffness between cellular structures and generate an effect that represents a platform technology in tattoo removal, cellulite treatment, fibrotic scar treatment and other indications. Its technology allows the disruption of targeted structures within the skin with minimal discomfort and without additional treatment-related downtime for tattoo removal or any downtime for cellulite treatment.

Employees

Sector

Advanced Medical Equipment & Technology

More about the company

Date	Insider	Type	Main position	Quantity	% Market Cap.
12/16/21 A	Niquette Hunt	Issuer sale	Director	30,000	0.1389%
12/16/21 A	Bradley Hauser	Issuer sale	Chief Executive Officer	610,000	2.8245%
12/16/21 A	Danika R. Harrison	Issuer sale	Director	60,000	0.2778%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SOLITON, INC.	+0.13%	+12.34%	-	-	488M
EL.EN. S.P.A.	+0.80%	-1.81%	+33.07%	+39.05%	1.41B
MODULIGHT OYJ	0.00%	+0.49%	-21.11%	-49.39%	51.1M
Average	+0.31%	-0.66%	+5.98%	-5.17%	732.04M
Weighted average by Cap.	+0.61%	-1.73%	+31.18%	+35.96%

Soliton, Inc. Stock

Stocks

SOLY

US8342511008

Advanced Medical Equipment & Technology

Latest news : Soliton, Inc.

Analysts' recommendations : Soliton, Inc.

Press Releases : Soliton, Inc.

Quotes and Performance

Managers and Directors : Soliton, Inc.

Latest insider transactions

Laser Equipment

Company Profile

20/12/21	Soliton, Inc.(NasdaqCM:SOLY) dropped from S&P TMI Index	CI
16/12/21	Soliton, Inc.(NasdaqCM:SOLY) dropped from NASDAQ Composite Index	CI
16/12/21	Allergan plc completed the acquisition of Soliton, Inc. for approximately $570 million.	CI
14/12/21	Soliton Up 12% as Nasdaq Alert Says Sale to AbbVie Is Scheduled to Close Thursday	DJ
13/11/21	Soliton, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	CI
12/08/21	Soliton, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	CI
02/07/21	Soliton : AbbVie, Soliton Providing FTC Extra Time to Review Proposed Deal	MT
02/06/21	Soliton : Roth Capital Downgrades Soliton to Neutral From Buy	MT
13/05/21	Soliton, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	CI
13/05/21	Soliton : Cantor Fitzgerald Downgrades Soliton to Neutral from Overweight, Adjusts Price Target to $22.60 from $25	MT
11/05/21	Soliton : Maxim Group Downgrades Soliton to Hold From Buy	MT
10/05/21	AbbVie : Allergan Aesthetics to Acquire Soliton for $22.60 per Share	MT
10/05/21	AbbVie's Allergan Aesthetics to Buy Soliton	DJ